semaglutide oral efficacy and safety of with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial Preference for Oral and Injectable

Our food is depleted in nutrients

doi: 10.1074/jbc.M701132200 79 TougaardPMartinsenLOLtzhftDOJensenHEFlethjMVandenabeelePet al

Clinical trials are done before a medication is approved by the FDA

For decades, GLP-1 stole the spotlight due to its potent appetite-suppressing and insulin-enhancing effects

The primary mechanisms of action include: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood glucose levels without causing hypoglycaemia when used alone Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production Slowing gastric emptying , which prolongs the feeling of fullness after meals Acting on appetite centres in the brain , particularly the hypothalamus, to reduce hunger and food intake GLP-1 receptor agonists are typically administered via subcutaneous injection, with dosing frequencies ranging from once daily to once weekly depending on the specific medication, though oral semaglutide (Rybelsus) is also available